Preclinical data has also suggested that the inhibition of CDK4/6 antagonises the effect of several types of chemotherapy, such as in combination with gemcitabine (the most common chemotherapy agent used in advanced PC [38]), by blocking chemotherapy-induced cytotoxicity. This evidence concerns the gene CDK4 and pachyonychia congenita.